Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2019 Aug 8;39(10):2145–2156. doi: 10.1161/ATVBAHA.119.312723

Figure 4: Relative abundances of apoC-III1 and apoC-III2 after apoC-III ASO treatment of a human cohort.

Figure 4:

Patients with hypertriglyceridemia were administered volanesorsen (300 mg, once weekly over 13 weeks) and plasma was analyzed at the beginning and the end (d = 85) of the study. (A) The relative abundance of apoC-III1 significantly decreased (p = 0.007) during the treatment period, whereas (B) the relative abundance of apoC-III2 significantly increased (p = 0.05) resulting in an increase in (C) the apoC-III2/apoC-III1 ratio (p = 0.03). Data represent means ± SEM.